Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Friday, March 29, 2024 · 699,658,504 Articles · 3+ Million Readers

New Therapeutic Drugs for Tendinitis Treatment Coming Down the Pipeline

There are around 4+ key companies that are developing therapies for Tendinitis. MiMedx has its drug candidate in the most advanced stage. However, the Tendinitis pipeline consists of fewer drugs, so there is an opportunity for different companies to work in this arena and dominate the market.

/EIN News/ -- Los Angeles, USA, June 21, 2021 (GLOBE NEWSWIRE) -- New Therapeutic Drugs for Tendinitis Treatment Coming Down the Pipeline 

There are around 4+ key companies that are developing therapies for Tendinitis. MiMedx has its drug candidate in the most advanced stage. However, the Tendinitis pipeline consists of fewer drugs, so there is an opportunity for different companies to work in this arena and dominate the market. 

DelveInsight’s “Tendinitis Pipeline Insight” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Tendinitis pipeline landscapes. It comprises Tendinitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Tendinitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Tendinitis pipeline products.     

Some of the key takeaways from the Tendinitis Pipeline Report  

  • Major companies such as MiMedx, R3 Stem Cell, Seikagaku Corporation, Dobecure, Zhejiang Xingyue Biotechnology, and others are developing potential drug candidates to improve the Tendinitis treatment scenario. 
  • In April 2021, MiMedx Group, an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that the last patients had completed their previous clinical visits in two late-stage Investigational New Drug (IND) trials: Phase 3 studies of AmnioFix Injectable (micronized dehydrated Human Amnion Chorion Membrane (mdHACM)) as a potential treatment for Plantar Fasciitis and Achilles Tendonitis. 

Get an overview of pipeline landscape @ Tendinitis Clinical Trials Analysis 

Tendinitis (also called tendonitis) is an inflammation or irritation of a tendon, a thick cord, which attaches bone to muscle. Tendinitis can occur in almost any area of the body. The most common places are the base of the thumb, elbow, shoulder, hip, knee, Achilles tendon.

Tendinitis Emerging Drugs

  • SI-613: Seikagaku Corporation

SI-613 is a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) are chemically bound utilizing Seikagaku’s proprietary technology. SI-613 was developed to offer pain relief and anti-inflammatory effect by sustained release of NSAID, and the joint function was enhanced by the effect of hyaluronic acid. It is anticipated to offer prompt and sustained relief from severe pain and inflammation associated with osteoarthritis and enthesopathy. The drug is currently in phase II of clinical trials for Tendinitis treatment.

  • MP1032: MetrioPharm

MP1032’s mode of action is to accelerate the healing process that allows for MP1032 as a therapeutic for tendinitis before tendinosis develops. In addition, MP1032 could speed up the repair of already damaged tendons and hence also decrease the duration of tendinosis treatments. The drug is currently in phase I of clinical trials for the treatment of tendinitis.

  • dHACM: MiMedx

dHACM is a micronized dehydrated Human Amnion Chorion Membrane developed by MiMedx for Tendinitis and is currently in the phase III stage of development. AmnioFix is processed using Purion, a unique patented method for placental-based allografts according to the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product faces active preservation of the extracellular matrix (ECM), regulatory proteins, and elimination of blood contaminants through a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized. 

For further information, refer to the detailed report @ Tendinitis Pipeline Therapeutics 

Scope of Tendinitis Pipeline Drug Insight    

  • Coverage: Global 
  • Major Players: 4+Key Players
  • Prominent Players: MiMedx, R3 Stem Cell, Seikagaku Corporation, Causeway Therapeutics, Zhejiang Xingyue Biotechnology, and many others.   
  • Key Drugs Profiles: 4+Products
  • Phases:  

·       Tendinitis Therapies Late-stage (Phase III)  
·       Tendinitis Therapies Mid-stage (Phase II)
·       Tendinitis Therapies Early-stage (Phase I) 
·       Tendinitis Pre-clinical stage and Discovery candidates     
·       Discontinued and Inactive candidates 

  • Mechanism of Action:

·       Cyclooxygenase inhibitors
·       Cell replacements, Tissue replacements
·       Collagen modulators; MicroRNA modulators

  • Molecule Types:   

·       Peptides
·       Monoclonal Antibody
·       Polymer
·       Small molecule
·       Gene therapy 

  • Route of Administration:

·       Oral
·       Parenteral
·       Intravitreal
·       Subretinal
·       Topical 

  • Product Types:

·       Monotherapy
·       Combination
·       Mono/Combination 

Key Questions regarding Current Tendinitis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

  • What are the current options for Tendinitis treatment?
  • How many companies are developing therapies for the treatment of Tendinitis? 
  • How many are Tendinitis emerging therapies in the early-stage, mid-stage, and late development stages to treat Tendinitis? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Tendinitis market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Tendinitis?  
  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Tendinitis therapies? 
  • What are the critical designations that have been granted for the emerging therapies for Tendinitis? 
  • How many patents are granted and pending for the emerging therapies to treat Tendinitis?   

Table of Contents

1 Tendinitis Report Introduction
2 Tendinitis Executive Summary
3 Tendinitis Overview
4 Tendinitis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment
5 Tendinitis Pipeline Therapeutics
6 Tendinitis Late Stage Products (Phase III)
6.1 dHACM: MiMedx
7 Tendinitis Mid Stage Products (Phase II/III)
7.1 Amniotic Fluid: R3 Stem Cell
8 Tendinitis Mid Stage Products (Phase II)
8.1 SI-613: Seikagaku Corporation
9 Tendinitis Early Stage Products (Phase I)
9.1 CWT 001: Causeway Therapeutics
10 Tendinitis Therapeutic Assessment
11 Tendinitis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Tendinitis Key Companies
14 Tendinitis Key Products
15 Tendinitis Unmet Needs
16 Tendinitis Market Drivers and Barriers
17 Tendinitis Future Perspectives and Conclusion
18  Tendinitis Analyst Views
19 Appendix
20 About DelveInsight

Get a customized pipeline report @ Tendinitis Drugs Pipeline Report  

Related Reports  

DelveInsight’s Krabbe Disease Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight’s Laryngeal Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight’s Nosocomial Pneumonia Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight’s Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 


Contact Us:
                    
                    Shruti Thakur 
                    
                    info@delveinsight.com   
                    
                    +1(919)321-6187 
                    
                    www.delveinsight.com 
                    
                     

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release